Suppr超能文献

血糖控制和使用胰岛素或胰岛素分泌促进剂治疗的老年患者的健康状况类别与糖尿病并发症:糖尿病与衰老研究。

Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study.

机构信息

Yale School of Medicine, New Haven, Connecticut, USA.

University of Chicago, Chicago, Illinois, USA.

出版信息

J Am Geriatr Soc. 2023 Dec;71(12):3692-3700. doi: 10.1111/jgs.18565. Epub 2023 Aug 28.

Abstract

BACKGROUND

For older adults with type 2 diabetes (T2D) treated with insulin or sulfonylureas, Endocrine Society guideline recommends HbA1c between 7% to <7.5% for those in good health, 7.5% to <8% for those in intermediate health, and 8% to <8.5% for those in poor health. Our aim was to examine associations between attained HbA1c below, within (reference), or above recommended target range and risk of complication or mortality.

METHODS

Retrospective cohort study of adults ≥65 years old with T2D treated with insulin or sulfonylureas from an integrated healthcare delivery system. Cox proportional hazards models of complications during 2019 were adjusted for sociodemographic and clinical variables. Primary outcome was a combined outcome of any microvascular or macrovascular event, severe hypoglycemia, or mortality during 12-month follow-up.

RESULTS

Among 63,429 patients (mean age: 74.2 years, 46.8% women), 8773 (13.8%) experienced a complication. Complication risk was significantly elevated for patients in good health (n = 16,895) whose HbA1c was above (HR 1.97, 95% CI 1.62-2.41) or below (HR 1.29, 95% CI 1.02-1.63) compared to within recommended range. Among those in intermediate health (n = 30,129), complication risk was increased for those whose HbA1c was above (HR 1.45, 95% CI 1.30-1.60) but not those below the recommended range (HR 0.99, 95% CI 0.89-1.09). Among those in poor health (n = 16,405), complication risk was not significantly different for those whose HbA1c was below (HR 0.98, 95% CI 0.89-1.09) or above (HR 0.96, 95% CI 0.88-1.06) recommended range.

CONCLUSIONS

For older adults with T2D in good health, HbA1c below or above the recommended range was associated with significantly elevated complication risk. However, for those in poor health, achieving specific HbA1c levels may not be helpful in reducing the risk of complications.

摘要

背景

对于接受胰岛素或磺酰脲类药物治疗的 2 型糖尿病(T2D)老年患者,内分泌学会指南建议健康状况良好者的糖化血红蛋白(HbA1c)目标值为 7%至<7.5%,健康状况中等者为 7.5%至<8%,健康状况不佳者为 8%至<8.5%。我们的目的是研究达到以下 HbA1c 水平与并发症或死亡风险之间的关系:低于、在(参考)或高于推荐目标范围。

方法

这是一项来自综合性医疗服务系统的 2019 年成年人≥65 岁的 T2D 患者接受胰岛素或磺酰脲类药物治疗的回顾性队列研究。对 12 个月随访期间的任何微血管或大血管事件、严重低血糖或死亡的并发症进行 Cox 比例风险模型调整,以调整社会人口统计学和临床变量。主要结局是任何微血管或大血管事件、严重低血糖或死亡率的复合结局。

结果

在 63429 名患者(平均年龄:74.2 岁,46.8%为女性)中,8773 名(13.8%)发生了并发症。健康状况良好(n=16895)的患者 HbA1c 高于(HR1.97,95%CI1.62-2.41)或低于(HR1.29,95%CI1.02-1.63)推荐范围时,其并发症风险显著升高。在健康状况中等(n=30129)的患者中,HbA1c 高于(HR1.45,95%CI1.30-1.60)的患者发生并发症的风险增加,但低于推荐范围的患者(HR0.99,95%CI0.89-1.09)风险未增加。在健康状况不佳(n=16405)的患者中,HbA1c 低于(HR0.98,95%CI0.89-1.09)或高于(HR0.96,95%CI0.88-1.06)推荐范围的患者并发症风险无显著差异。

结论

对于健康状况良好的 T2D 老年患者,HbA1c 低于或高于推荐范围与并发症风险显著升高相关。然而,对于健康状况不佳的患者,达到特定的 HbA1c 水平可能无助于降低并发症风险。

相似文献

3
Potential overtreatment of diabetes mellitus in older adults with tight glycemic control.
JAMA Intern Med. 2015 Mar;175(3):356-62. doi: 10.1001/jamainternmed.2014.7345.
7
Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Diabetes Technol Ther. 2014 Dec;16(12):833-9. doi: 10.1089/dia.2014.0039. Epub 2014 Jul 28.
8
Reducing hypoglycemia from overtreatment of type 2 diabetes in older adults: The HypoPrevent study.
J Am Geriatr Soc. 2023 Dec;71(12):3701-3710. doi: 10.1111/jgs.18566. Epub 2023 Sep 21.
9
Assessing potential glycemic overtreatment in persons at hypoglycemic risk.
JAMA Intern Med. 2014 Feb 1;174(2):259-68. doi: 10.1001/jamainternmed.2013.12963.

引用本文的文献

本文引用的文献

1
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
N Engl J Med. 2023 Jun 15;388(24):2301-2302. doi: 10.1056/NEJMc2301923.
2
13. Older Adults: Standards of Care in Diabetes-2023.
Diabetes Care. 2023 Jan 1;46(Suppl 1):S216-S229. doi: 10.2337/dc23-S013.
3
Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2023 Feb 15;108(3):529-562. doi: 10.1210/clinem/dgac596.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
6
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
7
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
8
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
9
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.
J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574. doi: 10.1210/jc.2019-00198.
10
Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes.
J Clin Endocrinol Metab. 2019 Jun 1;104(6):1989-1998. doi: 10.1210/jc.2018-01402.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验